{"id":102804,"date":"2026-06-08T15:09:10","date_gmt":"2026-06-08T15:09:10","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/102804\/"},"modified":"2026-06-08T15:09:10","modified_gmt":"2026-06-08T15:09:10","slug":"novo-nordisk-pfizer-roche-incyte-treeline-readout-newsletter","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/102804\/","title":{"rendered":"Novo Nordisk, Pfizer, Roche, Incyte, Treeline: Readout Newsletter"},"content":{"rendered":"<p>Want to stay on top of the science and politics driving biotech today?\u00a0<a href=\"https:\/\/www.statnews.com\/signup\/readout\/\" rel=\"nofollow noopener\" target=\"_blank\">Sign up<\/a>\u00a0to get our biotech newsletter in your inbox.<\/p>\n<p>Gene therapies can now cure disease, but America still hasn\u2019t figured out how to pay for them. Is there a better way? Also, Novo executives are downplaying a once-coveted obesity drug, Incyte is making a $2 billion blood disease bet, and new data suggest Boehringer\u2019s obesity contender may struggle to stand out in an increasingly crowded market.<\/p>\n<p>The need-to-know this morning<\/p>\n<p>Roche is <a href=\"https:\/\/www.roche.com\/media\/releases\/med-cor-2026-06-08\" rel=\"noopener nofollow\" target=\"_blank\">partnering<\/a> with Nurix Therapeutics to co-develop an experimental antibody treatment that works by degrading, or eliminating, a protein called BTK that is associated with blood cancer and other diseases.\u00a0<\/p>\n<p>Treeline Biosciences, the developer of early-stage cancer medicines co-founded by biotech entrepreneur Josh Bilenker,\u00a0is going public via a <a href=\"https:\/\/treeline.bio\/press\/standard-biotools-and-treeline-biosciences-announce-merger-agreement\" rel=\"noopener nofollow\" target=\"_blank\">reverse merger<\/a> with Standard BioTools.\u00a0<\/p>\n<p>Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate<\/p>\n<p>Revolution Medicines\u2019 experimental pancreatic cancer drug <a href=\"https:\/\/www.statnews.com\/2026\/05\/31\/pancreatic-cancer-daraxonrasib-revolution-medicines-results-asco-2026\/\" rel=\"nofollow noopener\" target=\"_blank\">has been the star of the oncology field<\/a> in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/dk\/wp-content\/uploads\/2026\/06\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus in-depth analysis, newsletters, premium events, and news alerts.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" rel=\"nofollow noopener\" target=\"_blank\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" rel=\"nofollow noopener\" target=\"_blank\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" rel=\"nofollow noopener\" target=\"_blank\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Want to stay on top of the science and politics driving biotech today?\u00a0Sign up\u00a0to get our biotech newsletter&hellip;\n","protected":false},"author":2,"featured_media":102805,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2759,4240,5794,272,5356],"class_list":["post-102804","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-biotechnology","tag-drug-development","tag-drug-prices","tag-novo-nordisk","tag-research"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/116715124738429541","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/102804","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=102804"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/102804\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/102805"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=102804"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=102804"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=102804"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}